Publisher
Springer Science and Business Media LLC
Subject
Public Health, Environmental and Occupational Health,Health Policy,Pharmacology
Reference39 articles.
1. Lakdawalla DN, Doshi JA, Garrison LP, Phelps CE, Basu A, Danzon PM. Defining elements of value in health care—a health economics approach: an ISPOR special task force REPORT [3]. Value in Health. 2018;21:131–9.
2. Garrison LPJ, Zamora B, Li M, Towse A. Augmenting cost-effectiveness analysis for uncertainty: the implications for value assessment-rationale and empirical support. J Manag Care Spec Pharm. 2020;26:400–6.
3. Neumann PJ, Willke RJ, Garrison LPJ. A health economics approach to US value assessment frameworks-introduction: an ISPOR Special Task Force Report [1]. Value Health. 2018;21:119–23.
4. Li M, Garrison LJ, Lee W, Kowal S, Wong W, Veenstra D. A Pragmatic Guide to Assessing Real Option Value for Medical Technologies. Value Health. 2022. https://doi.org/10.1016/j.jval.2022.05.014.
5. Li M, Basu A, Bennette C, Veenstra D, Garrison LP. How does option value affect the potential cost-effectiveness of a treatment? The case of ipilimumab for metastatic melanoma. Value in Health. 2019;22:777–84.